Pure Global AI
NCT06286150Recruiting

Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery

Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery: A Prospective, Single Center Study
The First Affiliated Hospital of Guangzhou Medical UniversityClinicalTrials.govprocedure
Verified
Study focus
Disease/Condition
Lung Cancer
Drug/Device/Intervention
Surgical robot system
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
The First Affiliated Hospital of Guangzhou Medical University
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Sep 15, 2023
End date
Jul 15, 2027
Enrollment
20 participants
Primary outcome

Intraoperative conversion rate,Surgical complications rate

Summary

Robotic surgical systems have become a promising surgical assistance system, with unique
 advantages such as 3D high-definition visual system, highly flexible wrist-jointed
 instruments, and automatic fitering of hand tremors. Robotic surgical systems is applied in
 various fields including urology, general surgery, cardiothoracic surgery, head and neck
 surgery, and gynecology. Currently, the Da Vinci surgical robot system is the most widely
 used robot system globally. However, the Da Vinci robot system for single-port laparoscopic
 surgery has not yet been launched in China. Therefore, the investigators conduct a
 prespective, single-center study to evaluate the efficacy and safety of single-port surgical
 robot system in thoracic surgery.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06286150
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06286150 through Pure Global AI's free database. This phase not specified trial is sponsored by The First Affiliated Hospital of Guangzhou Medical University and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.